Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

v3.22.2.2
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2022
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended

    

Nine-Month Periods Ended

​

​

September 30, 

​

September 30, 

($ in thousands)

    

2022

    

2021

    

2022

    

2021

Qbrexza®

​

$

6,265

​

$

6,636

​

$

19,752

​

$

11,204

Accutane®

​

 

4,121

​

 

3,531

​

 

14,228

​

 

5,672

Amzeeq

​

​

1,161

​

​

—

​

​

5,892

​

​

—

Targadox®

​

​

1,168

​

​

5,184

​

​

6,558

​

​

18,110

Ximino®

​

​

1,773

​

​

2,864

​

​

3,775

​

​

6,277

Zilxi

​

​

554

​

​

—

​

​

1,851

​

​

—

Exelderm®

​

 

1,001

​

 

1,366

​

 

3,018

​

 

4,319

Other branded revenue

​

 

—

​

 

29

​

 

—

​

 

35

Total product revenues

​

$

16,043

​

$

19,610

​

$

55,074

​

$

45,617

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended

 

Nine-Month Periods Ended

​

​

September 30, 

 

September 30, 

($ in thousands)

    

2022

    

2021

    

2022

    

2021

Other revenue

 

​

73

 

​

—

​

​

2,629

 

​

—

Total other revenue

​

$

73

​

$

—

​

$

2,629

​

$

—